thyroid
| 3 min read
The acquisition includes clinical stage anti-IGF-1R monoclonal antibody VRDN-001, which is intended for treatment of thyroid eye disease
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Maximizing NGS efficiency with magnetic beads
The latest magnetic bead technology cuts sample preparation time, producing consistent, reliable results.
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
